drugset / Trial / NCT02807974

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

NCT02807974

Phase 3 Completed 51 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.

Timeline

Start
2016-06
Primary completion
2017-03
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CS-3150 Unknown 1.25 mg Oral
Subject CS-3150 Unknown 2.5 mg Oral
Subject CS-3150 Unknown 5 mg Oral

Indications